Last reviewed · How we verify

Daratumumab, Ixazomib, Dexamethasone — Competitive Intelligence Brief

Daratumumab, Ixazomib, Dexamethasone (Daratumumab, Ixazomib, Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Oncology.

phase 2 Monoclonal antibody CD38 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Daratumumab, Ixazomib, Dexamethasone (Daratumumab, Ixazomib, Dexamethasone) — Hellenic Society of Hematology. Daratumumab is a monoclonal antibody that targets CD38.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Daratumumab, Ixazomib, Dexamethasone TARGET Daratumumab, Ixazomib, Dexamethasone Hellenic Society of Hematology phase 2 Monoclonal antibody CD38
Darzalex Faspro daratumumab-and-hyaluronidase-fihj Pfizer marketed CD38-directed Cytolytic Antibody [EPC] CD38 2020-01-01
Darzalex daratumumab Johnson & Johnson marketed Monoclonal antibody CD38 2015-01-01
DARATUMUMAB (DARZALEX®) DARATUMUMAB (DARZALEX®) Hospices Civils de Lyon marketed CD38-targeting monoclonal antibody CD38
Daratumumab Hyaluronidase-fihj Daratumumab Hyaluronidase-fihj Memorial Sloan Kettering Cancer Center marketed CD38-targeting monoclonal antibody CD38
SCT800 and Daratumumab SCT800 and Daratumumab Institute of Hematology & Blood Diseases Hospital, China marketed Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab) CD19 and CD3 (SCT800); CD38 (Daratumumab)
SARCLISA ISATUXIMAB-IRFC SANOFI AVENTIS US marketed CD38-directed Cytolytic Antibody [EPC] Lymphocyte differentiation antigen CD38

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daratumumab, Ixazomib, Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/daratumumab-ixazomib-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: